Serap Yalçın Azarkan

This review article states that pharmacogenomics explains individual drug-response variation at the genetic level while artificial intelligence improves diagnostic accuracy, risk assessment, and treatment strategy through analysis of large and complex clinical, genetic, and imaging datasets, and that combining the two can support more individualized cardiovascular care and better clinical decision-making, though data security, ethical concerns, and insufficient clinical validation still limit widespread adoption.

This review article states that pharmacogenomics explains individual drug-response variation at the genetic level while artificial intelligence improves diagnostic accuracy, risk assessment, and treatment strategy through analysis of large and complex clinical, genetic, and imaging datasets, and that combining the two can support more individualized cardiovascular care and better clinical decision-making, though data security, ethical concerns, and insufficient clinical validation still limit widespread adoption.